38 related articles for article (PubMed ID: 22733292)
1. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
3. Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk.
Kwon J; Suessmilch M; McColl A; Cavanagh J; Morris BJ
Sci Rep; 2021 Dec; 11(1):23841. PubMed ID: 34903784
[TBL] [Abstract][Full Text] [Related]
4. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Dovedi SJ; Melis MH; Wilkinson RW; Adlard AL; Stratford IJ; Honeychurch J; Illidge TM
Blood; 2013 Jan; 121(2):251-9. PubMed ID: 23086756
[TBL] [Abstract][Full Text] [Related]
6. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis reveals TLR7 dynamics underlying antagonism.
Tojo S; Zhang Z; Matsui H; Tahara M; Ikeguchi M; Kochi M; Kamada M; Shigematsu H; Tsutsumi A; Adachi N; Shibata T; Yamamoto M; Kikkawa M; Senda T; Isobe Y; Ohto U; Shimizu T
Nat Commun; 2020 Oct; 11(1):5204. PubMed ID: 33060576
[TBL] [Abstract][Full Text] [Related]
8. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
Patinote C; Karroum NB; Moarbess G; Cirnat N; Kassab I; Bonnet PA; Deleuze-Masquéfa C
Eur J Med Chem; 2020 May; 193():112238. PubMed ID: 32203790
[TBL] [Abstract][Full Text] [Related]
9. TLR-7 Stress Signaling in Differentiating and Mature Eosinophils Is Mediated by the Prolyl Isomerase Pin1.
Shen ZJ; Hu J; Kashi V; Bochkov YA; Gern JE; Malter JS
J Immunol; 2018 Dec; 201(12):3503-3513. PubMed ID: 30397031
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth.
Qiu J; Peng S; Yang A; Ma Y; Han L; Cheng MA; Farmer E; Hung CF; Wu TC
Oncoimmunology; 2018; 7(8):e1463946. PubMed ID: 30221059
[No Abstract] [Full Text] [Related]
11. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor Activity of Toll-Like Receptor 7 Agonists.
Chi H; Li C; Zhao FS; Zhang L; Ng TB; Jin G; Sha O
Front Pharmacol; 2017; 8():304. PubMed ID: 28620298
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Dovedi SJ; Lipowska-Bhalla G; Beers SA; Cheadle EJ; Mu L; Glennie MJ; Illidge TM; Honeychurch J
Cancer Immunol Res; 2016 Jul; 4(7):621-630. PubMed ID: 27241845
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.
Dovedi SJ; Adlard AL; Ota Y; Murata M; Sugaru E; Koga-Yamakawa E; Eguchi K; Hirose Y; Yamamoto S; Umehara H; Honeychurch J; Cheadle EJ; Hughes G; Jewsbury PJ; Wilkinson RW; Stratford IJ; Illidge TM
Oncotarget; 2016 Mar; 7(13):17035-46. PubMed ID: 26959743
[TBL] [Abstract][Full Text] [Related]
15. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
[TBL] [Abstract][Full Text] [Related]
16. Chemokine function in periodontal disease and oral cavity cancer.
Sahingur SE; Yeudall WA
Front Immunol; 2015; 6():214. PubMed ID: 25999952
[TBL] [Abstract][Full Text] [Related]
17. Dual roles of TLR7 in the lung cancer microenvironment.
Dajon M; Iribarren K; Cremer I
Oncoimmunology; 2015 Mar; 4(3):e991615. PubMed ID: 25949912
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
